Treatment

Karen Abbott, PhD

August 18, 2019

Karen Abbott, PhDUniversity of Georgia Targeting Tumor-Specific Glycosylation: Discovery of Novel Membrane Receptors Dr. Abbott’s work is focused on discovering new tumor-specific targets on the surface of cancer cells. Tumor-targeted therapy regimens will have less toxic side effects to normal tissues, and lead to a better quality of life for patients. This project is based […]

Read More

Lavakumar Karyampudi, PhD

August 17, 2019

Lavakumar Karyampudi, PhDMayo Clinic PD1 regulated dendritic cells: A target for ovarian cancer immunotherapy Immunosuppression that prevails in ovarian tumor microenvironment is the main reason for the recurrence of disease in ovarian cancer patients. Blockade of suppressor cells and/or immune inhibitory networks during vaccination has great chance at reducing recurrence among patients. PD-1/B7-H1 axis is […]

Read More

Tyler Curiel, MD, MPH

August 17, 2019

Tyler Curiel, MD, MPHUniversity of Texas Health Science Center at San Antonio Improving B7-H1 blockade to treat ovarian cancer Immunotherapy theoretically should be effective for ovarian cancer but only has modest effects because of ovarian cancer-related immune dysfunction. Dr. Curiel will use a well-established pre-clinical mouse model to test rationally designed combinations of agents that […]

Read More

Lin Zhang, MD

August 17, 2019

Lin Zhang, MDUniversity of Pennsylvania Reconstruction of the Heterochronic Pathway for Ovarian Cancer Treatment The heterochronic pathway orchestrates the timing of cell divisions and fates during development. Its core elements, LIN28 and the microRNA let-7, form bistable switches via a double-negative regulatory loop. Dr. Zhang has previously reported that let-7 is downregulated in epithelial ovarian […]

Read More

Yunfei Wen, PhD

August 17, 2019

Yunfei Wen, PhDUniversity of Texas MD Anderson Cancer Center Suicidal Autophagy: Targeting Tumoral PRL/PRLR Axis in Ovarian Cancer G129R, a molecular antagonist to tumoral PRLR, robustly inhibits tumor growth through formation of excessive autophagosomes in ovarian cancer cells. Dr. Wen will explore the regulatory mechanism of G129R-induced autophagy in ovarian cancer cells and therapeutically evaluate […]

Read More

Karen Lounsbury, PhD

August 17, 2019

Karen Lounsbury, PhDUniversity of Vermont and State Agricultural College Protein Translation Regulators and the Ovarian Cancer Microenvironment The Lounsbury/Francklyn labs have discovered a role for the enzyme threonyl tRNA synthetase (TARS) in promoting blood vessel growth (angiogenesis) in ovarian cancer. These studies led to the characterization of a selective TARS inhibitor that reduces angiogenesis in […]

Read More

Hani Gabra, PhD, FRCP

August 17, 2019

Hani Gabra, PhD, FRCPImperial College London Therapeutic Delivery of OPCML Tumor Suppressor Protein Using Virus-Like Particles Tumor suppressor proteins are natural cellular defense mechanisms against cancer because they keep tumor-causing proteins under control by promoting their degradation. OPCML is such a tumor suppressor; however, it is inactive in most cases of ovarian cancer. Dr. Gabra’s […]

Read More

Bin Zhang, MD, PhD

August 17, 2019

Bin Zhang, MD, PhDNorthwestern University Treating ovarian cancer with novel ecto-5’nucleotidase (CD73) inhibitors Tumors have elaborate suppressive mechanisms against host immune system to enhance their survival. Ovarian tumors highly express a protein called CD73 that limits anti-tumor immune response in order to promote tumor growth. Dr. Zhang‘s recent research demonstrates that CD73 may serve as […]

Read More

Kwong-Kwok Wong, PhD

August 17, 2019

Kwong-Kwok Wong, PhDUniversity of Texas MD Anderson Cancer Center Targeted Therapy for Ovarian Clear Cell Carcinoma Patients with late stage clear cell ovarian carcinoma have poorer survival rates than the more common high-grade serous ovarian carcinomas. Current therapies are not effective for this aggressive cancer. Dr. Wong‘s preliminary data suggests that targeting the mTOR pathway, […]

Read More

Peter Kuhn, PhD

August 17, 2019

Peter Kuhn, PhDUniversity of Southern California Single-cell molecular profiling of biopsies of epithelial cancer Next-generation sequencing of single cancer cells identified from the blood of ovarian cancer patients can potentially guide treatment decisions, identify recurrence early, and lead to earlier and more accurate diagnosis of the disease. Dr. Kuhn will use a “fluid biopsy” to […]

Read More